Predictors and outcome associated with an Enterococcus positive isolate during intensive care unit admission

Anaesthesia and Intensive Care

Volumn 37, Issue 6, 2009, Pages 976-982

  Chatterjee, I ^a,b   Dulhunty, J M ^a,c   Iredell, J ^a,d   Gallagher, J E ^a,e   Sud, A ^a,f   Woods, M ^a,c   Lipman, J ^a,c  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b TOOWOOMBA HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f NEPEAN HOSPITAL   (Australia)

Author keywords

Cefepime; Enterococcus spp.; Imipenen; Incidence; Intensive care; Meropenem; Nasogastric tube; Renal replacement therapy

Indexed keywords

AMPICILLIN; CEFEPIME; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; CONTROLLED STUDY; DISEASE SEVERITY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; FEMALE; HOSPITAL ADMISSION; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NASOGASTRIC TUBE; NONHUMAN; OUTCOME ASSESSMENT; RENAL REPLACEMENT THERAPY; SEPSIS;

EID: 74049085020     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0903700610     Document Type: Article

References (35)

1. Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev 1990; 3:46-65.
2. Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991; 91:86S-89S.
3. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol 2000; 21:510-515.
4. Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988; 1:57-58.
5. Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37:997-1005.
6. L efort A, Mainardi JL, Tod M, Lortholary O. Antienterococcal antibiotics. Med Clin North Am 2000; 84:1471-1495.
7. Chatterjee I, Iredell JR, Woods M, Lipman J. The implications of enterococci for the intensive care unit. Crit Care Resusc 2007; 9:69-75.
8. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-829.
9. Nimmo GR, Bell JM, Collignon PJ. Fifteen years of surveillance by the Australian Group for Antimicrobial Resistance (AGAR). Commun Dis Intell 2003; 27 (Suppl):S47-54.
10. Alvarez Lerma F, Palomar M, Insausti J, Olaechea P, Alcala MA, Blanco A. [Enterococcal infections in critically ill patients admitted to ICU]. Med Clin (Barc) 2003; 121:281-286.
11. Routsi C, Platsouka E, Paniara O, Dimitriadou E, Saroglou G, Roussos C et al. Enterococcal infections in a Greek intensive care unit: a 5-y study. Scand J Infect Dis 2000; 32:275-280.
12. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993; 42:597-599.
13. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000, issued June 2000. Am J Infect Control 2000; 28:429-448.
14. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003; 31:481-498.
15. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 2004; 50:59-69.
16. Bouchillon SK, Johnson BM, Hoban DJ, Johnson JL, Dowzicky MJ, Wu DH et al. Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002. Int J Antimicrob Agents 2004; 24:119-124.
17. Goetz AM, Rihs JD, Wagener MM, Muder RR. Infection and colonization with vancomycin-resistant Enterococcus faecium in an acute care Veterans Affairs Medical Center: a 2-year survey. Am J Infect Control 1998; 26:558-562.
18. L autenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999; 20:318-323.
19. Peset V, Tallon P, Sola C, Sanchez E, Sarrion A, Perez-Belles C et al. Epidemiological, microbiological, clinical, and prognostic factors of bacteremia caused by high-level vancomycin-resistant Enterococcus species. Eur J Clin Microbiol Infect Dis 2000; 19:742-749.
20. Sitges-Serra A, Lopez MJ, Girvent M, Almirall S, Sancho JJ . Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg 2002; 89:361-367.
21. Bhavnani SM, Drake JA, Forrest A, Deinhart JA, Jones RN, Biedenbach DJ et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000; 36:145-158.
22. Edmond MB, Ober JF, Weinbaum DL, Pfaller MA, Hwang T, Sanford MD et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995; 20:1126-1133.
23. L ucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998; 26:1127-1133.
24. Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis 2004; 39:219-226.
25. Paterson DL, Muto CA, Ndirangu M, Linden PK, Potoski BA, Capitano B et al. Acquisition of rectal colonization by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those receiving cefepime-containing antibiotic regimens. Antimicrob Agents Chemother 2008; 52:465-469.
26. L andry SL, Kaiser DL, Wenzel RP. Hospital stay and mortality attributed to nosocomial enterococcal bacteremia: a controlled study. Am J Infect Control 1989; 17:323-329.
27. Shay DK, Maloney SA, Montecalvo M, Banerjee S, Wormser GP, Arduino MJ et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995; 172:993-1000.
28. Sotto A, Lefrant JY, Fabbro-Peray P, Muller L, Tafuri J, Navarro F et al. Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis. J Antimicrob Chemother 2002; 50:569-576.
29. L odise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin Infect Dis 2002; 34:922-929.
30. Vergis EN, Hayden MK, Chow JW, Snydman DR, Zervos MJ, Linden PK et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Ann Intern Med 2001; 135:484-492.
31. Jaccard C, Troillet N, Harbarth S, Zanetti G, Aymon D, Schneider R et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42:2966-2972.
32. Bryan CS, Reynolds KL, Brown JJ. Mortality associated with enterococcal bacteremia. Surg Gynecol Obstet 1985; 160:557-561.
33. Rohrborn A, Wacha H, Schoffel U, Billing A, Aeberhard P, Gebhard B et al. Coverage of enterococci in community acquired secondary peritonitis: results of a randomized trial. Surg Infect (Larchmt) 2000; 1:95-107.
34. Gorbach SL. Intraabdominal infections. Clin Infect Dis 1993; 17:961-965.
35. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115:529-535.